{
    "organizations": [],
    "uuid": "23450f247759ffc4b936f12037192aa6ebafa885",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neotract-announces-fda-clearance-o/brief-neotract-announces-fda-clearance-of-expanded-indications-for-urolift-system-idUSFWN1QA02K",
    "ord_in_thread": 0,
    "title": "BRIEF-Neotract Announces FDA Clearance Of Expanded Indications For Urolift System",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Teleflex Inc:\n* NEOTRACT ANNOUNCES FDA CLEARANCE OF EXPANDED INDICATIONS FOR UROLIFTÂ® SYSTEM\n* NEOTRACT - EXPANDED INDICATIONS MEAN PATIENTS WITH OBSTRUCTIVE MEDIAN LOBE, AS YOUNG AS 45 NOW ELIGIBLE TO GET TREATMENT WITH UROLIFT FOR BPH SYMPTOMS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T19:43:00.000+02:00",
    "crawled": "2018-02-21T21:30:38.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "teleflex",
        "inc",
        "neotract",
        "announces",
        "fda",
        "clearance",
        "expanded",
        "indication",
        "system",
        "neotract",
        "expanded",
        "indication",
        "mean",
        "patient",
        "obstructive",
        "median",
        "lobe",
        "young",
        "eligible",
        "get",
        "treatment",
        "urolift",
        "bph",
        "symptom",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}